Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Phase 1bexobrutidegvenetoclaxPositive

AI Analysis

Summary

Nurix Therapeutics announced the first patient enrollment in a Phase 1b/2 combination study evaluating bexobrutideg with venetoclax for chronic lymphocytic leukemia treatment.

Clinical Trial Data

Phase

1b/2

Patients

Importance:5/10

Sentiment:

0.30

clinical_trialphase_1b_2combination_therapyoncologychronic_lymphocytic_leukemia

Related Companies

$NRIX

Read the original article

Published by GlobeNewswire Pharma on October 7, 2026 5:00 AM

Read Original